Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?
Abstract Percutaneous and surgical therapies for septal reduction for hypertrophic cardiomyopathy have been going head‐to‐head for the past 20 years with similar outcomes and mortality rates, although contemporary myectomy seems to materialize its superiority. However, on closer analysis, the extern...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.14272 |
| _version_ | 1827945265628184576 |
|---|---|
| author | Alexandru Achim Adela Mihaela Serban Stefan Dan Cezar Mot Gregor Leibundgut Madalin Marc Ulrich Sigwart |
| author_facet | Alexandru Achim Adela Mihaela Serban Stefan Dan Cezar Mot Gregor Leibundgut Madalin Marc Ulrich Sigwart |
| author_sort | Alexandru Achim |
| collection | DOAJ |
| description | Abstract Percutaneous and surgical therapies for septal reduction for hypertrophic cardiomyopathy have been going head‐to‐head for the past 20 years with similar outcomes and mortality rates, although contemporary myectomy seems to materialize its superiority. However, on closer analysis, the external validity of studies advocating myectomy does not translate to all centres. The aim of this review was to examine the most recent data on septal reduction therapy and to attempt to phenotype the appropriate patient for each of the two treatments. The key to similar low mortality rates between ventricular septal myectomy and alcohol septal ablation appears to be proper patient selection performed in high volume clinical environments. Furthermore, we analyse the role of mavacampten (the recently approved cardiac myosin inhibitor) in replacing or complementing the two septal reduction therapies. |
| first_indexed | 2024-03-13T10:42:14Z |
| format | Article |
| id | doaj.art-8c7e2650afb7477f880c6b3e4d83b407 |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-03-13T10:42:14Z |
| publishDate | 2023-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-8c7e2650afb7477f880c6b3e4d83b4072023-05-18T03:08:57ZengWileyESC Heart Failure2055-58222023-06-011031570157910.1002/ehf2.14272Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?Alexandru Achim0Adela Mihaela Serban1Stefan Dan Cezar Mot2Gregor Leibundgut3Madalin Marc4Ulrich Sigwart5‘Niculae Stancioiu’ Heart Institute University of Medicine and Pharmacy ‘Iuliu Hatieganu’ Cluj‐Napoca Romania‘Niculae Stancioiu’ Heart Institute University of Medicine and Pharmacy ‘Iuliu Hatieganu’ Cluj‐Napoca Romania‘Niculae Stancioiu’ Heart Institute University of Medicine and Pharmacy ‘Iuliu Hatieganu’ Cluj‐Napoca RomaniaKlinik für Kardiologie Medizinische Universitätsklinik Liestal Switzerland‘Niculae Stancioiu’ Heart Institute University of Medicine and Pharmacy ‘Iuliu Hatieganu’ Cluj‐Napoca RomaniaUniversity of Geneva Geneva SwitzerlandAbstract Percutaneous and surgical therapies for septal reduction for hypertrophic cardiomyopathy have been going head‐to‐head for the past 20 years with similar outcomes and mortality rates, although contemporary myectomy seems to materialize its superiority. However, on closer analysis, the external validity of studies advocating myectomy does not translate to all centres. The aim of this review was to examine the most recent data on septal reduction therapy and to attempt to phenotype the appropriate patient for each of the two treatments. The key to similar low mortality rates between ventricular septal myectomy and alcohol septal ablation appears to be proper patient selection performed in high volume clinical environments. Furthermore, we analyse the role of mavacampten (the recently approved cardiac myosin inhibitor) in replacing or complementing the two septal reduction therapies.https://doi.org/10.1002/ehf2.14272Hypertrophic cardiomyopathyAlcohol septal ablationSeptal myectomyMitral valveLeft ventricular outflow tract obstructionOutcomes |
| spellingShingle | Alexandru Achim Adela Mihaela Serban Stefan Dan Cezar Mot Gregor Leibundgut Madalin Marc Ulrich Sigwart Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients? ESC Heart Failure Hypertrophic cardiomyopathy Alcohol septal ablation Septal myectomy Mitral valve Left ventricular outflow tract obstruction Outcomes |
| title | Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients? |
| title_full | Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients? |
| title_fullStr | Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients? |
| title_full_unstemmed | Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients? |
| title_short | Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients? |
| title_sort | alcohol septal ablation in hypertrophic cardiomyopathy for which patients |
| topic | Hypertrophic cardiomyopathy Alcohol septal ablation Septal myectomy Mitral valve Left ventricular outflow tract obstruction Outcomes |
| url | https://doi.org/10.1002/ehf2.14272 |
| work_keys_str_mv | AT alexandruachim alcoholseptalablationinhypertrophiccardiomyopathyforwhichpatients AT adelamihaelaserban alcoholseptalablationinhypertrophiccardiomyopathyforwhichpatients AT stefandancezarmot alcoholseptalablationinhypertrophiccardiomyopathyforwhichpatients AT gregorleibundgut alcoholseptalablationinhypertrophiccardiomyopathyforwhichpatients AT madalinmarc alcoholseptalablationinhypertrophiccardiomyopathyforwhichpatients AT ulrichsigwart alcoholseptalablationinhypertrophiccardiomyopathyforwhichpatients |